Targeted PET/CT predicts early treatment response in rheumatoid arthritis patients
Peer-Reviewed Publication
Updates every hour. Last Updated: 1-Jun-2026 09:16 ET (1-Jun-2026 13:16 GMT/UTC)
A team from the Monash University Biomedicine Discovery Institute in Australia has identified a tick-derived evasin that can bind to two major classes of chemokines, a discovery that is important for the development of therapeutics targeting inflammatory and autoimmune diseases. Until now, scientists had identified only evasins that selectively block chemokines within a single class.
Recommendation based on Phase II/III study demonstrating up to 96 per cent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sickness
The therapy, given as a single dose of three tablets, could offer a simpler alternative to longer, more complex regimens and help support the World Health Organization’s (WHO) goal of eliminating the disease by 2030
Sanofi will donate the medicine to WHO through its philanthropic arm Foundation S